• The OD segment has become extremely attractive with multiple blockbusters, with most of the major 10 pharma companies engaging in OD development.
• It is, therefore, unclear if the rare disease incentives put in place to encourage OD development are still necessary.  And if so, should they be revised to ensure only the drugs most needed are developed?
• Today most large companies have invested in the OD field as a new route for developing blockbusters with an unexpectedly high return on investment.
• Simultaneously it seems the incentives in place are prioritizing a number of specific therapeutic areas such as oncology.  In fact, the development of monoclonal antibodies and companion diagnostics has lead to multiple opportunities in oncology.
CONCLUSIONS
• OD policies have seemingly reached their objectives, as there is distinct increase in the number of OD approved.
• The data supports the belief that the OD area will provide a good return on investment for pharmaceutical companies.
• OD policy appears to be unnecessary to incentivize the development of drugs that will achieve blockbuster status.
• It is, therefore, important to revisit the orphan drug regulation to direct policy towards treatments for rare diseases which have so far been neglected.
OBJECTIVE
• The objective of this study is to review the overall performance of OD policies on development and revenue of OD.
METHODS
• On the FDA and EMA websites website we identified the yearly number of OD approved. We gathered revenues associated with OD from the perspective of the companies and individual products, through IMS sales database, syndicated reports, and company websites including annual reports. We also reviewed published OD forecasts.
RESULTS
1. Orphan drug revenue is outstanding. Even though there is the stereotype that orphan drug companies generate small revenue, the reality is very different. Thanks to the indication expansion strategy, many pharma companies has managed to attained products that has achieved the blockbuster status.  For instance, Infliximab (Remicade ® , Novartis) has achieved almost $ 9bn total brand sale. This product was first for the treatment of Crohn's disease an orphan indication, and later it has gained the approval of non-orphan indications, like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis.
 Another successful example of this strategy is Adalimumab (Humira ® , Abbott) which was first approved for rheumatoid arthritis and then pursued the strategy of indication expansion till achieve as today 9 therapeutic indications, generating $8.2bn in sales in 2011.  Biologics (mainly monoclonal antibodies and therapeutic proteins) represent >40% of FDA approved OD. However, they account for almost two thirds of annual OD sales (Figure 2 ).  For these reasons, OD prices are high and the return on investment is likely to be significant in the long run. 
